{
  "id": 5876429,
  "title": "Xenon (XENE) Heads To Europe With Data That Could Reshape Epilepsy Care",
  "url": "https://urgent.news/2026/09/04/xenon-xene-heads-to-europe-with-data-that-could-reshape-epilepsy-care",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-04T19:06:11.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/xenon-xene-heads-europe-data-190611721.html"
  },
  "original_language": "en",
  "account": "Xenon Pharmaceuticals is set to present six data sets at the 16th European Epilepsy Congress in Athens, Greece, from September 5 to 9. The highlight is an oral presentation of the top results from the Phase 3 X-TOLE2 study on azetukalner, a new drug for focal onset seizures. Along with two posters, the presentation will showcase the long-term seizure reduction and safety of patients who have been in the ongoing X-TOLE Open Label Extension study for at least 48 months. Another poster will present the mechanism behind azetukalner, detailing how it interacts with KV7 potassium channels and its potential to work with existing antiseizure medications. This scientific spotlight is crucial as Xenon Pharmaceuticals edges closer to a regulatory decision. The drug works by opening KV7 potassium channels, a mechanism different from existing antiseizure medications, which could allow patients who do not respond to other treatments to benefit from azetukalner. Moreover, the potential of azetukalner to complement current treatments, rather than replace them, is underscored by recent data. Xenon Pharmaceuticals has also submitted pre-NDAA meeting with regulators and anticipates seeking approval for azetukalner for focal onset seizures in the third quarter of 2026. The drug has already been discussed at the American Academy of Neurology meeting in Chicago and the Epilepsy Foundation Pipeline Conference in Virginia. While Xenon's net loss widened to $110.7 million in the second quarter of 2026, driven by increased research and development spending, the company is optimistic about its expanding neuropsychiatry trials and the upcoming NDA filing. However, the progress of the trials, including X-TOLE3 and X-ACKT epilepsy studies and a neuropsychiatry bet, remains uncertain. Hedge fund ownership of Xenon Pharmaceuticals slightly decreased, suggesting a cautious investor sentiment. The next critical phase for Xenon Pharmaceuticals lies in the submission of its NDA, where strong Phase 3 data, an expanding pipeline in neuropsychiatry and pain, and sufficient cash reserves could potentially lead to a successful outcome.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}